Cargando…

Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population‐based nested case–control study

AIMS: To assess the association between concurrent use of potential pharmacokinetic or pharmacodynamic interacting drugs and major bleeding among direct oral anticoagulant (DOAC) users. METHODS: We performed a case–control study nested in a cohort of new users of DOACs (dabigatran etexilate, apixaba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yumao, Souverein, Patrick C., Gardarsdottir, Helga, van den Ham, Hendrika A., Maitland‐van der Zee, Anke‐Hilse, de Boer, Anthonius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256117/ https://www.ncbi.nlm.nih.gov/pubmed/32022295 http://dx.doi.org/10.1111/bcp.14227

Ejemplares similares

Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants
por: Hempenius, Mirjam, et al.
Publicado: (2021)

Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation
por: Souverein, Patrick C., et al.
Publicado: (2020)

Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population‐based cohort studies
por: van den Ham, Hendrika A., et al.
Publicado: (2021)

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study
por: Rustem Gulluoglu, Fatma, et al.
Publicado: (2020)

Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
por: Verhoef, Talitha I., et al.
Publicado: (2014)

Systematic Review of Pharmacogenetic Warfarin Dosing
por: van Schie, Rianne M. F., et al.
Publicado: (2009)

Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors
por: Mahmoudpour, Seyed Hamidreza, et al.
Publicado: (2015)

Pharmacogenomic insights into treatment and management of statin-induced myopathy
por: Peters, Bas JM, et al.
Publicado: (2009)

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study
por: Ibáñez, Luisa, et al.
Publicado: (2019)

The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2020)

Pharmacogenetics and pharmacogenomics: practical applications in routine medical practice
por: Maitland-van der Zee, Anke-Hilse, et al.
Publicado: (2010)

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022)

Quality of reporting of drug exposure in pharmacoepidemiological studies
por: Hempenius, Mirjam, et al.
Publicado: (2020)

Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Ahmadizar, Fariba, et al.
Publicado: (2015)

Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Ahmadizar, Fariba, et al.
Publicado: (2015)

Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
por: Hempenius, Mirjam, et al.
Publicado: (2019)

Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact
por: Hempenius, Mirjam, et al.
Publicado: (2021)

Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands
por: van den Heuvel, Jan Maurik, et al.
Publicado: (2020)

New‐user and prevalent‐user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices
por: Luijken, Kim, et al.
Publicado: (2021)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study
por: Hempenius, Mirjam, et al.
Publicado: (2022)

Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016
por: Christos, Steve, et al.
Publicado: (2016)

From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
por: Wilffert, Bob, et al.
Publicado: (2010)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Evaluation of Patient Characteristics Linked to Major Bleeding Events in Patients Prescribed Direct Oral Anticoagulants
por: Kanaan, Dareen M., et al.
Publicado: (2023)

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
por: van den Heuvel, J. M., et al.
Publicado: (2018)

Reversal agents for oral anticoagulant-associated major or life-threatening bleeding
por: Moia, Marco, et al.
Publicado: (2019)

Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019–2020? A cross-sectional study in ClinicalTrials.gov
por: de Jong, Amos J, et al.
Publicado: (2022)

Bleeding complications from the direct oral anticoagulants
por: Sholzberg, Michelle, et al.
Publicado: (2015)

Gastrointestinal toxicity among patients taking selective COX‐2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case–control study
por: Bakhriansyah, Mohammad, et al.
Publicado: (2017)

Risk of myocardial infarction associated with non‐steroidal anti‐inflammatory drugs: Impact of additional confounding control for variables collected from self‐reported data
por: Bakhriansyah, Mohammad, et al.
Publicado: (2019)

Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine
por: Maagdenberg, Hedy, et al.
Publicado: (2016)

Genetic Factors of Renin–Angiotensin System Associated with Major Bleeding for Patients Treated with Direct Oral Anticoagulants
por: Yee, Jeong, et al.
Publicado: (2022)

Asthmatic children that are uncontrolled despite inhaled corticosteroids have a distinct breathprint (the pacman2 study)
por: Vijverberg, Susanne, et al.
Publicado: (2015)

This Article Corrects: “Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016”
por: Christos, Steve, et al.
Publicado: (2016)

Correction to: Reversal agents for oral anticoagulant-associated major or life-threatening bleeding
por: Moia, Marco, et al.
Publicado: (2019)

Prothrombin complex concentrate in the management of major bleeding induced by oral anticoagulant therapy
por: AlSheef, Mohammed, et al.
Publicado: (2022)

Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis
por: Maura, Géric, et al.
Publicado: (2018)

Respiratory tract infection and risk of bleeding in oral anticoagulant users: self-controlled case series
por: Ahmed, Haroon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t05ga2c5jp1snc90tic9fnfljs